Results 51 to 60 of about 34,892 (272)

Corticobasal syndrome: neuroimaging and neurophysiological advances [PDF]

, 2019
Corticobasal degeneration (CBD) is a neurodegenerative condition characterized by 4R-tau protein deposition in several brain regions that clinically manifests itself as a heterogeneous atypical parkinsonism typically expressing in the adulthood.
Asci, Francesco, Berardelli, Alfredo, Bologna, Matteo, Colosimo, Carlo, Di Stasio, Flavio, Fabbrini, Giovanni, Marsili, Luca, Pantano, Patrizia, Suppa, Antonio, Upadhyay, Neeraj   +9 more
core   +1 more source

Fluid Biomarkers of Disease Burden and Cognitive Dysfunction in Progressive Supranuclear Palsy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F‐PI‐2620 tau‐PET, clinical, and cognitive outcomes.
Roxane Dilcher, Charles B. Malpas, Stuart J. McDonald, William T. O’Brien, Craig Despott, Kelly L. Bertram, Matthew P. Pase, Lukas Frontzkowski, Meng Law, Terence J. O’Brien, Lucy Vivash   +10 more
wiley   +1 more source

The Effectiveness of Exercise Programs on Balance, Functional Ability, Quality of Life, and Depression in Progressive Supranuclear Palsy: A Case Study

Applied Sciences
Progressive supranuclear palsy is a form of atypical Parkinsonism. People living with Progressive Supranuclear Palsy have various symptoms, such as movement and cognitive disorders, which mainly affect balance and functional ability with an increased ...
Panagiotis Papamichail, Michail Michalas, Dimitris Krokos, Maria Balamoutsou, Panagiota Karkoula, Epameinondas Lyros, Vasiliki Sakellari, Anna Christakou   +7 more
doaj   +1 more source

Gene-Environment Interactions in Progressive Supranuclear Palsy

Frontiers in Neurology, 2021
Several genetic and environmental factors have been reported in progressive supranuclear palsy (PSP), although none were identified as a definitive cause. We aimed to explore potential gene-environment interactions in PSP.
Irene Litvan, James A. Proudfoot, Eden R. Martin, David Standaert, David Riley, Deborah Hall, Connie Marras, Ece Bayram, Richard M. Dubinsky, Yvette Bordelon, Stephen Reich, David Shprecher, David Shprecher, Benzi Kluger, Christopher Cunningham, Gerard D. Schellenberg, Joseph Jankovic   +16 more
doaj   +1 more source

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study

The Lancet: Digital Health, 2019
Summary: Background: Development of valid, non-invasive biomarkers for parkinsonian syndromes is crucially needed. We aimed to assess whether non-invasive diffusion-weighted MRI can distinguish between parkinsonian syndromes using an automated imaging ...
Derek B Archer, PhD, Justin T Bricker, MS, Winston T Chu, BS, Roxana G Burciu, PhD, Johanna L McCracken, BS, Song Lai, ProfPhD, Stephen A Coombes, PhD, Ruogu Fang, PhD, Angelos Barmpoutis, PhD, Daniel M Corcos, PhD, Ajay S Kurani, PhD, Trina Mitchell, MS, Mieniecia L Black, MPH, Ellen Herschel, BS, Tanya Simuni, ProfMD, Todd B Parrish, ProfPhD, Cynthia Comella, ProfMD, Tao Xie, MD, Klaus Seppi, ProfMD, Nicolaas I Bohnen, ProfMD, Martijn LTM Müller, PhD, Roger L Albin, ProfMD, Florian Krismer, MD, Guangwei Du, MD, Mechelle M Lewis, PhD, Xuemei Huang, ProfMD, Hong Li, PhD, Ofer Pasternak, PhD, Nikolaus R McFarland, MD, Michael S Okun, ProfMD, David E Vaillancourt, ProfPhD   +30 more
doaj   +1 more source

Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program [PDF]

, 2017
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's ...
Albin, Roger, Alcalay, Roy N., Babcock, Debra, Bowman, F. DuBois, Chen-Plotkin, Alice, David, Karen K., Dawson, Ted M., Dewey, Richard B., Jr., Foroud, Tatiana, German, Dwight, Gwinn, Katrina, Huang, Xuemei, Lungu, Codrin, Petyuk, Vlad, Potashkin, Judith A., Rosenthal, Liana S., Saunders-Pullman, Rachel, Scherzer, Clemens R., Sieber, Beth-Anne, St Hillaire-Clarke, Coryse, Sutherland, Margaret, Swanson-Fischer, Christine, Vaillancourt, David E., Walt, David R., West, Andrew B., Zhang, Jing   +25 more
core   +1 more source

A Systematic Comparison of Alpha‐Synuclein Seed Amplification Assays for Increasing Reproducibility

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Seed amplification assays (SAAs) enable ultrasensitive detection of misfolded α‐synuclein across biofluids and tissues. Yet, heterogeneity in protocols limits cross‐study comparability and clinical translation. Here, we review α‐synuclein SAA methods and their performance across various biological matrices.
Manuela Amaral‐do‐Nascimento, Daniela F. Santos, Tuane C. R. G. Vieira, Tiago F. Outeiro   +3 more
wiley   +1 more source

Progressive Supranuclear Palsy [PDF]

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1987
ABSTRACT:Progressive supranuclear palsy (PSP) was first recognized as a distinct morbid entity by Richardson, Steele and Olszewski a quarter century ago. Subsequent experience has confirmed and extended their original observations. PSP has become familiar as a chronic progressive disorder with extrapyramidal rigidity, bradykinesia, gait impairment ...
Joseph Jankovic, Haydee Rohaidy
openaire   +1 more source

Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options [PDF]

, 2016
There are currently no disease-modifying treatments for progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or therapeutic treatments that are effective in controlling their symptoms.
Andrew J. Lees, Huw R. Morris, Jonathan D. Rohrer, Ruth Lamb   +3 more
core   +1 more source